Subsequent Events	6 Months Ended
Jun. 30, 2026
Subsequent Events [Abstract]
Subsequent Events	12. Subsequent Events On July 14, 2026, the Company entered into an Amended and Restated Technology Transfer and Exclusive License Agreement with Mabworks Biotech Co., Ltd., which amended and restated the parties’ existing agreement dated January 8, 2025. The amended agreement reflects the advancement of the parties’ collaboration and establishes a framework for additional collaboration on development activities, including clinical trials, as may be mutually agreed by the parties. The milestone payment and royalty provisions of the original agreement remain unchanged. The Company is evaluating the accounting impact of the amended agreement.

The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 855
-Name Accounting Standards Codification
-Publisher FASB
-URI https://asc.fasb.org/855/tableOfContent

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 855
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483399/855-10-50-2

Name:	us-gaap_SubsequentEventsTextBlock
Namespace Prefix:	us-gaap_
Data Type:	dtr-types:textBlockItemType
Balance Type:	na
Period Type:	duration